Strategic Equity Capital plc · LSE:SEC

Strategic Equity Capital — Q3 2019 Earnings Presentation

37 slides from Strategic Equity Capital's earnings presentation, 2019

  1. Slide 1: Strategic Equity Capital plc Q3 Update 2019

    STRATEGIC EQUITY CAPITAL PLC Q3 Update 2019

  2. Slide 2: Risk considerations

    Risk considerations Risk Factors for Strategic Equity Capital plc (the Company”) – The general risk factors set out under the heading “D.1.Key Risks” of the Prospectus apply to the Company. In addition, potential investors should note the following factors: • There can be no guarantee that the inves

  3. Slide 3: Notice to recipients

    Notice to recipients This document is given to the recipient on condition that the recipient accepts that it is not a client of GVQ Investment Management Limited (“GVQIM”) and that hence, none of the client protections applicable to GVQIM’s clients are in fact in force or available, and GVQIM is not

  4. Slide 4: Contents

    Contents Q3 Update 2019 • Executive Summary 6 • Performance 7 • Detailed portfolio analysis 8 Outlook 13 Conclusion 22 Appendix 24 4

  5. Slide 5: Q3 Update 2019

    Q3 UPDATE 2019

  6. Slide 6: Executive summary

    Executive summary • SEC (the “Trust”) net assets per share decreased by 1.1%¹ over Q3. The FTSE Small Cap ex IT index (the “index”) decreased by 1.2%¹ • In 2019 YTD, the NAV per share has increased by 12.2%. This compares favourably with the FTSE Small Cap ex IT and FTSE AIM indices, which have incr

  7. Slide 7: Fund performance

    Fund performance Annualised 15 13.7 13.2 12.2 10.5 10 8.4 5.9 5.7 4.9 5 3.0 1.7 0.2 0 -1.1 -1.2 -5 -7.8 -10 3 months YTD 1 year 7 Feb 2017* 3 years 5 years 7 years SEC NAV Total Return FTSE Small Cap x IT Total Return Average 7.8% 8.0% 7.7% 8.3% 9.1% 9.4% 9.8% Net Cash Strong NAV return over the med

  8. Slide 8: Q3 Attribution analysis

    Q3 Attribution analysis Positive attribution bps GVQIM Comment Proactis 81 In-line full year results. In response to inbound interest, the company commences a Formal Sales Process Full year results, first under the new CEO with a return to organic growth. Shares remain very attractively Wilmington 7

  9. Slide 9: Changes to top 10 holdings

    Changes to top 10 holdings Top 10 Q2 2019 Top 10 Q3 2019 Company % of portfolio Company % of portfolio Equiniti Group 12.2 Equiniti Group 12.4 Tyman Group 6.6 Wilmington 7.8 Clinigen Group 6.5 Clinigen Group 7.3 Tribal Group 6.5 Tyman Group 6.7 Wilmington 6.4 Tribal Group 5.6 4imprint Group 6.3 Ergo

  10. Slide 10: Top 10 holdings

    Top 10 holdings1 GVQIM GVQIM Net debt/ Company Sector Funds % of CF yield2 Investment thesis EBITDA NTM3 company NTM3 High quality market leader in defensive and structurally growing market. Ability to grow Support through demonstrable cross-sell, penetrating the North American market and through se

  11. Slide 11: Highly concentrated and unconstrained portfolio

    Highly concentrated and unconstrained portfolio Sector exposure by value Value by market cap band 1 Healthcare 26.6% 12 1 <£50m 1.9% 8 9 7 7 2 Support services 18.4% 2 £50m - £100m 0.0% 1 3 6 3 Technology 15.8% 3 £100m - £200m 28.2% 4 Financials 11.1% 4 £200m - £300m 13.1% 6 5 5 Industrials 8.4% 5 £

  12. Slide 12: Portfolio valuation

    Portfolio valuation1 SEC SEC FTSE UK Small Cap ex weighted average median investment trusts Number of securities 21 21 154 Market cap (£m) 442 271 313 Consensus EV/EBITDA FY1 9.3x 9.5x 7.0x Consensus price earnings FY1 13.2x 13.2x 7.5x Consensus FY1 earnings growth 9.3% 10.0% 7.0% Consensus dividend

  13. Slide 13: Outlook

    OUTLOOK

  14. Slide 14: Small companies are currently out of favour

    Small Companies are currently out of favour… 400% Figure 1: 10 year cumulative performance by sector 300% • Small companies tend to outperform over the longer term (Figure 1) 200% 100% • This is a function of their greater ability to grow (from a smaller base) and being less well known and not as wi

  15. Slide 15: Negative flows and poor liquidity

    …coupled with negative flows and poor liquidity… IA UK Smaller Companies Funds cumulative net flows % of free float traded / month – FTSE Small Cap £0m 7% -£150m 6% -£300m 5% 4% -£450m 3% -£600m 2% -£750m 1% 0% -£900m 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 20

  16. Slide 16: Valuation divergence has rarely been wider

    Valuation divergence has rarely been wider FTSE Small Cap valuation discount to FTSE All Share (in P/E multiple terms) over time 1.0x 0.5x 0.0x -0.5x -1.0x -1.5x -2.0x -2.5x -3.0x 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 Small Cap discount t

  17. Slide 17: Global private equity dry powder at record highs

    Whilst global private equity dry powder levels are at record highs Private Equity Dry Powder by Fund Type, 2009 - YTD2019 Global public-to-private deal value $1,400bn $500 bn 200 $1,200bn $1,000bn $400 bn 150 Deal count Deal value $800bn $300 bn $600bn 100 $200 bn $400bn 50 $200bn $100 bn $0bn $0 bn

  18. Slide 18: Global private equity financing is generationally low

    Global private equity financing is generationally low Investor views on funds types presenting the best opportunities1 HY bond yields over time (Bloomberg global high yield bond index) 2 25% Buyout - Small to mid-market 54% Growth 29% 20% Secondaries 23% Buyout - Large to mega 18% 15% VC - Early sta

  19. Slide 19: Multi-year bearishness around UK equities

    Multi-year bearishness around UK equities Price and trailing DPS of UK MSCI index over time 240 200 160 120 80 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Price Trailing DPS Highly negative view of UK equities reflected in >£12bn of net outflows from UK funds

  20. Slide 20: Bear market checklist

    Bear market checklist Start of Proper Bear Markets Mar-00 Oct-07 Now Global Equity Valuations Trailing PE 33 17 18 Fwd PE 24 14 15 DY 1.3 2.1 2.5 CAPE 48 30 24 Global Equity Risk Premium 1.0% 3.3% 5.2% US Yield Curve (10Y minus 2Y) -0.5 0.0 0.0 Sentiment Global Analyst Bullishness (std dev) 1.7 1.0

  21. Slide 21: Earnings growth, cashflow and M&A to drive returns

    Earnings growth, cashflow and M&A to drive returns SEC portfolio • Double digit aggregate earnings • Private Equity ‘dry powder’ at record growth for the portfolio levels. Any resolution to UK uncertainty could see acquirers • Portfolio growth exceeds the market, return despite portfolio’s much lowe

  22. Slide 22: Conclusion

    CONCLUSION

  23. Slide 23: Conclusion

    Conclusion • SEC’s net assets per share (“NAV”) decreased by 1.1%¹ over Q3, whilst the FTSE Small Cap ex IT index decreased by 1.2% • In 2019 YTD, the NAV per share has increased by 12.2%. This compares favourably with the FTSE Small Cap ex IT and FTSE AIM indices, which have increased by 4.9% and 2

  24. Slide 24: Appendix

    APPENDIX

  25. Slide 25: Equiniti – a reminder of the thesis

    Equiniti – a reminder of the thesis Equiniti – a market leading specialist technology and business process outsourcer • Customers include 70% of FTSE 100 • High value on the strength of cash flows companies and 70% of newly listed and structural growth drivers to both PE companies and trade: • Oppor

  26. Slide 26: IFG Group – takeover case-study

    IFG Group – takeover case-study 2.00 Company announces proposed sale of Saunderson • On 25 March 2019, a recommended cash offer was made by Epiris House and potential Elysian Fuels liability Funds at 193p, a 46% premium to the closing share price, a trailing 1.90 PE valuation of 21.4x. SEC owned 9.9

  27. Slide 27: Medica Group – a recap of the company

    Medica Group – a recap of the company 40% 25 6 35% 4 20 30% 2 Operating margin 25% 0 15 Sales £m £m 20% -2 15% 10 -4 10% -6 5 5% -8 0% 0 -10 H117 H217 H118 H218 H119 H117 H217 H118 H218 H119 Sales EBITDA margin Operating cash flow Net debt/cash No. of reporters 267 306 339 362 390 • Since listing, t

  28. Slide 28: Medica Group – Investment Thesis

    Medica Group – Investment Thesis Medica Group – the UK’s leading teleradiology provider • Average sales growth rate of c.17% • High growth, predictable revenue since IPO. All organic streams and low capital intensity are coveted by financial buyers • This growth is supported by multiple long term st

  29. Slide 29: Portfolio investment themes

    Portfolio investment themes DIVERSIFIED DIGITAL HEALTH REGULATION AND PENSIONS INFRASTRUCTURE PHARMA COMPLIANCE AND AND SAVINGS BUILDING Demographic and Digital maturity agenda; Increase in complexity US single family Increasing compliance population changes replacement of legacy and regulatory burd

  30. Slide 30: How we identify value in potential investments

    How we identify value in potential investments Main focus of most Main focus of most PUBLIC EQUITY INVESTORS PRIVATE EQUITY INVESTORS All investments undergo All investments are valued in-house, prospective using an in house cash-flow and historic leveraged buy-out model modelling Focus on recent re

  31. Slide 31: Asset quality

    There are strict criteria for inclusion in our funds Speculative Fair valued GARP1 Under valued Recovery Turnaround Distress growth A A Investment Asset quality Asset quality focus B Avoid Avoid B C Avoid C GVQIM’s research process aims to identify high quality coveted assets with attractive cash fl

  32. Slide 32: How we identify coveted assets

    How we identify coveted assets We look for characteristics which GVQIM believes potential acquirers value highly Qualitative Quantitative • Niche market leaders • High and/or improving ROCE • Orderly end markets, with some growth • Strong cash conversion • Sustainable business model/franchise/unique

  33. Slide 33: Our Black List screens out companies with fundamental business risks

    Our Black List screens out companies with fundamental business risks Operational • Excessive reliance on a single product, customer, supplier or distributor • The primary driver of profitability cannot be influenced by management (e.g. resources) • Inherently low margins • Structurally declining mar

  34. Slide 34: Research Committee ensures consistency of approach

    Research Committee ensures consistency of approach Preliminary Investment Final Investment Monitoring Idea generation Investment Memorandum Recommendation & review Recommendation Materials • Watch list • Company description • Company meeting • Counterparty analysis • Progress against • M&A transacti

  35. Slide 35: Long term track record

    Long term track record Cumulative rebased total returns1 300 CAGR¹ 280 SEC NAV 18.2% 260 240 220 200 180 160 FTSE Small Cap ex IT 11.8% 140 120 100 80 60 40 Jun 09 Jun 10 Jun 11 Jun 12 Jun 13 Jun 14 Jun 15 Jun 16 Jun 17 Jun 18 Jun 19 Strong cumulative performance since process improvements in June 2

  36. Slide 36: Performance

    Performance Calendar Year annual performance YTD 2019 2018 2017 2016 2015 2014 2013 2012 Share Price Total Return 12.0% -17.6% 20.2% -9.0% 14.2% 32.7% 61.5% 25.6% NAV Total Return 12.2% -14.1% 21.7% 6.3% 12.1% 18.1% 46.1% 21.3% FTSE Small Cap ex Investment Trusts Total Return 4.9% -13.8% 15.6% 12.5%

  37. Slide 37: Contact details

    Contact details For further information regarding the SEC please contact the GVQ Investment Management marketing team below, or visit the Company’s website: www.strategicequitycapital.com For general enquiries, please contact: GVQ Investment Management Limited 16 Berkeley Street, London, W1J 8DZ Tel

Strategic Equity Capital — Q3 2019 Earnings Presentation on 6ix